Minireviews
Copyright ©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Dec 10, 2014; 5(5): 1028-1035
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.1028
Table 4 Special Situations about Toxicities of Zaltrap
Geriatric UseThe effect of ZALTRAP on overall survival was similar in patients < 65 yr old and ≥ 65 yr old who received ZALTRAP/FOLFIRI.
No dose adjustment of ZALTRAP is recommended for patients ≥ 65 yr of age.
Paediatric UseThe safety in paediatric patients has not been established.
Hepatic ImpairmentNo dedicated clinical studies have been conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of ziv-aflibercept.
Renal Impairment Contraception and Nursing MothersNo dedicated clinical studies have been conducted to evaluate the effect of renal impairment on the pharmacokinetics of ziv-aflibercept.
Females and males of reproductive potential should use highly effective contraception during and up to a minimum of 3 mo after the last dose of treatment.
OverdoseNo information on the safety of aflibercept given at doses exceeding 7 mg/kg every 2 wk or 9 mg/kg every 3 wk is present.
No specific antidote to ZALTRAP overdose exists.
Patients of Zaltrap overdose should be managed with supportive measures.
InfectionsThe Velour study showed an increased incidence of infections in patients receiving ZALTRAP/FOLFIRI (46%, all grades; 12%, Grade 3-4) than in patients receiving placebo/FOLFIRI (33%, all grades; 7%, Grade 3-4), including urinary tract infection, nasopharyngitis, upper respiratory tract infection, pneumonia, catheter site infection, and tooth infection.
Be vigilant about recognizing them.
Treat them according to general guidelines.